Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) EBT (2018 - 2025)

Serina Therapeutics (SER) has disclosed EBT for 8 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • Quarterly EBT fell 15.07% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Dec 2025, down 37.9% year-over-year, with the annual reading at -$19.2 million for FY2025, 71.29% down from the prior year.
  • EBT hit -$6.4 million in Q4 2025 for Serina Therapeutics, roughly flat from -$6.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $65000.0 in Q4 2023 to a low of -$6.4 million in Q4 2025.
  • Historically, EBT has averaged -$3.2 million across 5 years, with a median of -$2.6 million in 2022.
  • Biggest five-year swings in EBT: skyrocketed 102.36% in 2023 and later crashed 8663.08% in 2024.
  • Year by year, EBT stood at -$2.3 million in 2021, then fell by 22.02% to -$2.8 million in 2022, then surged by 102.36% to $65000.0 in 2023, then plummeted by 8663.08% to -$5.6 million in 2024, then fell by 15.07% to -$6.4 million in 2025.
  • Business Quant data shows EBT for SER at -$6.4 million in Q4 2025, -$6.4 million in Q3 2025, and -$5.6 million in Q2 2025.